SKL-27969 is under clinical development by SK Life Science and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SKL-27969’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SKL-27969 is under development for the treatment of advanced solid tumors, oligodendrogliomas, glioblastoma multiforme (GBM), non-small cell lung cancer, triple-negative breast cancer (TNBC), high-grade glioma. The drug candidate acts by targeting protein arginine methyltransferase 5 (PRMT5). It is administered through oral route.
SK Life Science overview
SK Life Science (SK Life) a subsidiary of SK Biopharmaceuticals Co Ltd is a developer of medicinal products. The company develops technologies in the areas of biology and discovery, medicinal chemistry and pharmacology. Its biology and discovery research provide lead compound discovery and optimization that indentifies and validates signal and molecular targets. SK Life develops drugs for epilepsy, sleep disorder, neuropathic pain, Alzheimer’s dementia, anxiety, depression, and schizophrenia. The company’s technical expertise includes continuous flow process and chiral chemistry. It develops drugs through partnerships with universities, government organizations, pharmaceutical and biotech companies. SK Life is headquartered in Fair Lawn, New Jersey, the US.
For a complete picture of SKL-27969’s drug-specific PTSR and LoA scores, buy the report here.